comparemela.com

Latest Breaking News On - Ulrik mouritzen - Page 2 : comparemela.com

Breye Therapeutics Strengthens Management Team and Board

/PRNewswire/ Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within.

Gabriela burianPeter adamsonUlrik mouritzenDanish innovation foundation innovationsfondenNovo holdingsDanish growth foundationHead of ophthalmology research at glaxosmithklineBioinnovation instituteChief scientificTherapeutics apsChief scientific officerVice presidentOphthalmology researchLead biologistTenpoint therapeuticsDiabetic retinopathy

Novo Holdings and Sound Bioventures launch Breye Therapeutics to develop novel oral therapies for ophthalmologic diseases

/PRNewswire/ Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within.

Ulrik mouritzenJim vanNovo nordiskZealand pharmaBioinnovation institutePartner at novo holdingsDanish growth foundationNovo groupScientific leadership teamHead of clinical developmentNovo holdingDanish innovation foundation innovationsfondenNovo nordisk foundationNovo holdingsChief executiveBreye therapeutics aps

Eye disease therapies being developed by Breye s €4M financing

Breye Therapeutics ApS developing therapies for retinal vascular diseases today closed a financing of €4 million.

Ulrik mouritzenJim van heusdenBioinnovation instituteDanish growth foundationNovo holdingDanish innovation foundation innovationsfondenNovo holdingsBreye therapeutics apsNovo seedEnovo seedsManaging partnerSound bioventuresDanish innovation foundationZealand pharma

vimarsana © 2020. All Rights Reserved.